Cerenion Oy is a science-based spin-off from the University of Oulu, Finland, that develops technology for the measurement of brain function during intensive care. Through our patented technology we seek to empower physicians with the first practical bed-side measurement of brain function. The team behind Cerenion has a long background in neurology, machine vision, in-depth biosignal analysis and the medical technology business.
We have developed the world’s ﬁrst practical method for measuring the brain function of intensive care patients. The patented Cerenion C-Trend® technology reveals the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The solution works by combining EEG-measurement with advanced machine learning algorithms (ML) and artificial intelligence (AI). The technology has the potential of improving both the quality and the cost of intensive care.
Cerenion C-Trend® is CE-marked as a Class IIb medical device in the European Union.
The spark for establishing Cerenion came when Dr. Jukka Kortelainen, MD PhD, one of the co-founders of the company, was completing his residency at the Department of Clinical Neurophysiology at the Oulu University Hospital.
While working in the Intensive Care Unit (ICU), Jukka realized just how little was known about the brain function of the patients treated at the ICU. The function of the heart and the lungs was monitored carefully, but little attention was often given to the brain even though it is perhaps the most vital of organs. This despite the fact that inadequate monitoring of brain function may significantly impair the treatment of the patient and increase the costs of care. This is what Cerenion set out to change.
Today, Cerenion has a portfolio of international patents, a growing body of clinical evidence from multisite studies and 10 employees at 2 locations in Finland. Our main office is located at the heart of the internationally recognized Oulu Health ecosystem in Oulu and our satellite office is located in the capital region.
You can meet us at either location, or at one of the many international conferences and trade fairs we take part in every year. Read more about upcoming events
"Finnish Cerenion has raised 500 000 euros in seed funding for its groundbreaking brain monitoring technology that holds great potential for improving intensive care…To date, the development of the technology and business has been funded by more than 1.1 million euros."
Good News from Finland
"Oulu’s ICT-focused enterprises are on track to raise a record amount of development capital in 2018, based on venture capital funding activity in January-February. Cerenion Oy is a case in point."
"Cerenion is a unique combination of deep research and a great complementary team that is creating a leader of a completely new category in healthcare. Their product will greatly help doctors in their work and save lives."
Riku Seppälä, Partner, Icebreaker.vc
"The team is a great combination of different kinds of skills and expertise. Furthermore, they’re very execution focused and they have taken the case far already before the investment, both in terms of product as well as clinical validation. Superb team together with strong IP, clear market entry path and scalable business model are the ingredients that Cerenion is made of."